Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
630 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis.
Chen QX, Zhou XY, Wu Q, Xie JJ, Xu Y, Teng FY, Guo M. · Endocrine · 2026 · cited 0 timesmeta-analysis, systematic review
- Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.
Santos-Pereira M, Frutuoso JF, Pereira SS, Guimarães M, Monteiro MP. · Front Endocrinol (Lausanne) · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis.
Spiazzi BF, Zingano CP, Colpani V, Gerchman F. · Diabetes Res Clin Pract · 2026 · cited 0 timesmeta-analysis, systematic review
- Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.
Amjad MM, Khan MM, Sarwar F, Ali A, Ali M, Bakhash F, Abid H, Ibrahim F, Mustafa K, Ali DE, Fayyaz MMN, Hassan H, Mian SM, Yaseen M, Qamar I, Khan AH, Ullah S, Khan BW. · Diabetes Obes Metab · 2026 · cited 0 timesmeta-analysis, systematic review
- Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.
Paccola GP, de Oliveira RF, Mochetti MM, Razera FPM, Vecchi R, Montanher RCP. · Clin Obes · 2026 · cited 0 timesOpen accessmeta-analysis, comparative study
- Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.
Zhou XY, Deng CH, Zhong JY, Wu Q, Chen QX, Gao XY, Xu Y, Jiang ZZ, Guo M, Teng FY. · Nutr Metab Cardiovasc Dis · 2026 · cited 1 timesmeta-analysis, systematic review
- Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA.
Falcon B, Xie CC, Redline S, Grunstein R, Turnbull CD, Rapoport DM, Wang H, Chakladar S, Dimitriadis GK, Lau E, Bednarik J, Liao B, Malhotra A. · J Clin Sleep Med · 2026 · cited 0 timesOpen accessclinical trial, phase iii, randomized controlled trial
- Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis.
Qi H, Gao Q, Chen H, Du X, Pan B. · PeerJ · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial.
Yokote K, Yamauchi T, Shingaki T, Chin R, Oura T, Nagai Y, Shimomura I, Kadowaki T. · Lancet Diabetes Endocrinol · 2026 · cited 0 timesclinical trial, phase iii, multicenter study
- Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis.
Quan AT, Nguyen HL, Nguyen TMT. · Diabetes Metab Syndr · 2026 · cited 0 timesmeta-analysis, systematic review
- Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.
Pałka W, Moćko P, Śladowska K, Holko P, Kawalec P. · J Endocrinol Invest · 2026 · cited 1 timesOpen accesssystematic review, network meta-analysis
- Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis.
Bhaduri G, Roy S, Kalia A, Gokalani R, Saboo B. · Clin Obes · 2026 · cited 0 timesmeta-analysis, systematic review
- Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
Sattar N, Linetzky B, Ruotolo G, Verma S, Sourij H, Wang H, Vanderman K, Wilson JM, Griffin RM, Stefanski A, Ridker PM. · J Am Coll Cardiol · 2026 · cited 2 timesclinical trial, phase iii, randomized controlled trial
- Long-term effects of weight-reducing drugs in people with hypertension.
Spary-Kainz U, Posch N, Radl-Karimi C, Jeitler K, Krenn C, Siebenhofer A, Berghold A, Horvath K, Winterholer S, Semlitsch T. · Cochrane Database Syst Rev · 2026 · cited 0 timesmeta-analysis, systematic review
- Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials.
Sattar N, Srinath R, García-Pérez LE, Lee CJ, Karanikas CA, Chen X, Plat A. · PLoS One · 2026 · cited 0 timesOpen accessrandomized controlled trial
- Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Damen JAA, Idema DL, Vernooij RWM, Huis In 't Veld LF, Kusters MPT, Lokerse ME, de Kanter E, Spijker R, van der Braak K, Jenniskens K, Oerbekke MS, Hooft L. · Ann Intern Med · 2026 · cited 5 timessystematic review, review
- Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Kamrul-Hasan ABM, Khalil I, Dutta D, Mahajan K, Nagendra L, Pappachan JM. · Endocrinol Diabetes Metab · 2026 · cited 0 timesOpen accessmeta-analysis, comparative study
- Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.
Kow CS, Thiruchelvam K, Ramachandram DS, Zaihan AF. · Endocrinol Diabetes Metab · 2026 · cited 0 timesOpen accessmeta-analysis
- SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity.
Rutter MK, Mount J, Gibson JM, Webb J, Marler C, Reed C, Gore M, Ye W, Gomez Valderas E, Wilding J, Sattar N, Davies MJ, Khunti K, Haynes R, Batterham RL. · Obesity (Silver Spring) · 2026 · cited 0 timesOpen accessmulticenter study, randomized controlled trial
- Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis.
Cheng PL, Chang HC. · Diabetes Res Clin Pract · 2026 · cited 0 timesmeta-analysis, systematic review
- Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs).
Laverde LP, Muñoz-Velandia OM, Alfonso D, Gómez Medina AM. · Int J Obes (Lond) · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
Nong K, Shi Q, Xie X, Wang Y, Agarwal A, Guyatt GH, Zhang H, Gao Y, Khunti K, Le Roux CW, Widyahening IS, Fan Q, Liu T, Mao Y, Florez ID, Du H, Pan X, Zou X, Wang C, Sun X, Li J, Hao Q, Jia Q, Sun F, Zhu Z, Agoritsas T, Tian H, Vandvik PO, Li S. · BMJ · 2026 · cited 4 timescomparative study, systematic review
- Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis.
Sebastian SA, Ayyalu T, Bimal T, Patel B, Kittleson MM, Carbone S, Yehya A. · Dis Mon · 2026 · cited 0 timesmeta-analysis, systematic review
- Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis.
Pisani D, Lorenza D, Fordellone M, Cerillo A, Fatigati M, Hanulíková P, Mariniello A, De Franciscis P, Pasquini L, La Verde M. · Endocrine · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Kanbay M, Shah E, AlShiab R, Ozbek L, Ay S, Rustamov A, Covic A, Mallamaci F, Zoccali C. · Diabetes Obes Metab · 2026 · cited 5 timesmeta-analysis, systematic review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.